AKT1 and chronic myelogenous leukemia, BCR-ABL1 positive: Figure 2D shows that, also in these CML cells, imatinib-resistance is associated with an increased phosphorylation of ERK1/2 Thr202/Tyr204 (more than 2-fold), Akt Ser473 (almost 2-fold) and rpS6 (about 5-fold).